Current biological therapies for use in HIV-positive patients with psoriasis: Case report of gesulkumab used and review

Gregory Bartos, Abigail Cline, Kourosh Beroukhim, Barbara A Burrall, Steven R. Feldman

Research output: Contribution to journalReview article

Abstract

Background: Psoriasis in human immunodeficiency virus (HlV)-positive patients may be severe. Physicians may be tentative to use biologies in HIV-infected patients. Objective: We present an HIV-positive patient with psoriasis who was treated with guselkumab. This paper aims to investigate the safety, efficacy, and tolerability of biologic therapies for HIV-positive patients with psoriasis. Methods: A systematic PubMed review of articles dating between 2000-2018 containing key words psoriasis AND HIV, and psoriatic AND HIV combined with several approved biologic therapies. The review generated 15 articles containing 27 cases of HIV-positive patients treated with etanercept, infliximab, adalimumab, or ustekinumab for their psoriasis. Results: The majority of cases reported excellent clinical responses, limited adverse events, and well tolerated treatment. CD4 count and viral loads were stable throughout treatment. Similar safety and efficacy were seen in the illustrative case report. Available literature is limited to case reports or case series and could be subject to publication bias of successful cases. Many reports lack quantifiable data and report results based on clinical judgement. No randomized, controlled trials evaluate biologic treatment for psoriasis in HIV-positive patients. Conclusions: The findings suggest that biologic therapy is an efficacious, safe, and tolerable treatment for most patients with moderate-to-severe psoriasis in HIV-positive patients.

Original languageEnglish (US)
Article number2
JournalDermatology Online Journal
Volume24
Issue number11
StatePublished - Nov 1 2018

Fingerprint

Biological Therapy
Psoriasis
HIV
Safety
Publication Bias
Therapeutics
CD4 Lymphocyte Count
Viral Load
PubMed
Randomized Controlled Trials
Physicians

Keywords

  • Adalimumab
  • Biologies
  • Etanercept
  • Guselkumab
  • Infliximab
  • Psoriasis
  • Psoriatic
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Current biological therapies for use in HIV-positive patients with psoriasis : Case report of gesulkumab used and review. / Bartos, Gregory; Cline, Abigail; Beroukhim, Kourosh; Burrall, Barbara A; Feldman, Steven R.

In: Dermatology Online Journal, Vol. 24, No. 11, 2, 01.11.2018.

Research output: Contribution to journalReview article

@article{d069298793a647868438870656f08cae,
title = "Current biological therapies for use in HIV-positive patients with psoriasis: Case report of gesulkumab used and review",
abstract = "Background: Psoriasis in human immunodeficiency virus (HlV)-positive patients may be severe. Physicians may be tentative to use biologies in HIV-infected patients. Objective: We present an HIV-positive patient with psoriasis who was treated with guselkumab. This paper aims to investigate the safety, efficacy, and tolerability of biologic therapies for HIV-positive patients with psoriasis. Methods: A systematic PubMed review of articles dating between 2000-2018 containing key words psoriasis AND HIV, and psoriatic AND HIV combined with several approved biologic therapies. The review generated 15 articles containing 27 cases of HIV-positive patients treated with etanercept, infliximab, adalimumab, or ustekinumab for their psoriasis. Results: The majority of cases reported excellent clinical responses, limited adverse events, and well tolerated treatment. CD4 count and viral loads were stable throughout treatment. Similar safety and efficacy were seen in the illustrative case report. Available literature is limited to case reports or case series and could be subject to publication bias of successful cases. Many reports lack quantifiable data and report results based on clinical judgement. No randomized, controlled trials evaluate biologic treatment for psoriasis in HIV-positive patients. Conclusions: The findings suggest that biologic therapy is an efficacious, safe, and tolerable treatment for most patients with moderate-to-severe psoriasis in HIV-positive patients.",
keywords = "Adalimumab, Biologies, Etanercept, Guselkumab, Infliximab, Psoriasis, Psoriatic, Ustekinumab",
author = "Gregory Bartos and Abigail Cline and Kourosh Beroukhim and Burrall, {Barbara A} and Feldman, {Steven R.}",
year = "2018",
month = "11",
day = "1",
language = "English (US)",
volume = "24",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "11",

}

TY - JOUR

T1 - Current biological therapies for use in HIV-positive patients with psoriasis

T2 - Case report of gesulkumab used and review

AU - Bartos, Gregory

AU - Cline, Abigail

AU - Beroukhim, Kourosh

AU - Burrall, Barbara A

AU - Feldman, Steven R.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Psoriasis in human immunodeficiency virus (HlV)-positive patients may be severe. Physicians may be tentative to use biologies in HIV-infected patients. Objective: We present an HIV-positive patient with psoriasis who was treated with guselkumab. This paper aims to investigate the safety, efficacy, and tolerability of biologic therapies for HIV-positive patients with psoriasis. Methods: A systematic PubMed review of articles dating between 2000-2018 containing key words psoriasis AND HIV, and psoriatic AND HIV combined with several approved biologic therapies. The review generated 15 articles containing 27 cases of HIV-positive patients treated with etanercept, infliximab, adalimumab, or ustekinumab for their psoriasis. Results: The majority of cases reported excellent clinical responses, limited adverse events, and well tolerated treatment. CD4 count and viral loads were stable throughout treatment. Similar safety and efficacy were seen in the illustrative case report. Available literature is limited to case reports or case series and could be subject to publication bias of successful cases. Many reports lack quantifiable data and report results based on clinical judgement. No randomized, controlled trials evaluate biologic treatment for psoriasis in HIV-positive patients. Conclusions: The findings suggest that biologic therapy is an efficacious, safe, and tolerable treatment for most patients with moderate-to-severe psoriasis in HIV-positive patients.

AB - Background: Psoriasis in human immunodeficiency virus (HlV)-positive patients may be severe. Physicians may be tentative to use biologies in HIV-infected patients. Objective: We present an HIV-positive patient with psoriasis who was treated with guselkumab. This paper aims to investigate the safety, efficacy, and tolerability of biologic therapies for HIV-positive patients with psoriasis. Methods: A systematic PubMed review of articles dating between 2000-2018 containing key words psoriasis AND HIV, and psoriatic AND HIV combined with several approved biologic therapies. The review generated 15 articles containing 27 cases of HIV-positive patients treated with etanercept, infliximab, adalimumab, or ustekinumab for their psoriasis. Results: The majority of cases reported excellent clinical responses, limited adverse events, and well tolerated treatment. CD4 count and viral loads were stable throughout treatment. Similar safety and efficacy were seen in the illustrative case report. Available literature is limited to case reports or case series and could be subject to publication bias of successful cases. Many reports lack quantifiable data and report results based on clinical judgement. No randomized, controlled trials evaluate biologic treatment for psoriasis in HIV-positive patients. Conclusions: The findings suggest that biologic therapy is an efficacious, safe, and tolerable treatment for most patients with moderate-to-severe psoriasis in HIV-positive patients.

KW - Adalimumab

KW - Biologies

KW - Etanercept

KW - Guselkumab

KW - Infliximab

KW - Psoriasis

KW - Psoriatic

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85059207729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059207729&partnerID=8YFLogxK

M3 - Review article

C2 - 30695971

AN - SCOPUS:85059207729

VL - 24

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 11

M1 - 2

ER -